Hybridoma cell strain secreting nifursolol residue marker monoclonal antibody

US10759845B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10759845-B2
Application numberUS-201816221719-A
CountryUS
Kind codeB2
Filing dateDec 17, 2018
Priority dateAug 9, 2018
Publication dateSep 1, 2020
Grant dateSep 1, 2020

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

A hybridoma cell strain secreting a nifursol residue marker monoclonal antibody with CGMCC No. 18525 is prepared in the following way: BALB/c mice are subjected to the first immunization with a complete Freund's adjuvant, subjected to booster immunization with an incomplete Freund's adjuvant for four times, and subjected to rush immunization once with nifursol residue marker complete antigen without a Freund's adjuvant so that the BALB/c mice are immunized; the spleen cells of the immunized mice with high titer and low IC50 were fused with mouse myeloma cells by a PEG method, and the fused cells are screened through indirect competitive ELISA and subcloned three times. The monoclonal antibody secreted by this cell strain has good specificity and detection sensitivity (IC50 value of 2 μg/L) to the nifursol residue marker and can be used for residue detection of the nifursol residual marker in food.

First claim

Opening claim text (preview).

What is claimed is: 1. A hybridoma cell strain secreting a nifursol residue marker monoclonal antibody, preserved at the China General Microbiological Culture Collection Center (Address: No. 3, #1 Yard, Beichen West Road, Chaoyang District, Beijing) on Oct. 14, 2019 with CGMCC No. 18525. 2. A nifursol residue marker monoclonal antibody which is secreted by the hybridoma cell strain of claim 1 .

Assignees

Inventors

Classifications

  • C07K16/44Primary

    against material not provided for elsewhere {, e.g. haptens, metals, DNA, RNA, amino acids} · CPC title

  • C07K16/065Primary

    Purification, fragmentation · CPC title

  • involving monoclonal antibodies {binding reaction mechanisms characterised by the use of monoclonal antibodies (G01N33/5302 - G01N33/576 take precedence)} · CPC title

  • Porphyrin- or corrin-ring-containing peptides · CPC title

  • Mycobacteriaceae (F) · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10759845B2 cover?
A hybridoma cell strain secreting a nifursol residue marker monoclonal antibody with CGMCC No. 18525 is prepared in the following way: BALB/c mice are subjected to the first immunization with a complete Freund's adjuvant, subjected to booster immunization with an incomplete Freund's adjuvant for four times, and subjected to rush immunization once with nifursol residue marker complete antigen wi…
Who is the assignee on this patent?
Univ Jiangnan
What technology area does this patent fall under?
Primary CPC classification C07K16/44. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Sep 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).